QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy.
LLerena
Adrián
A
Berecz
Roland
R
de la Rubia
Alfredo
A
Dorado
Pedro
P
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D003647:Debrisoquin / Q000378:metabolism* / Q000652:urine; D005260:Female; D008401:Gas Chromatography-Mass Spectrometry; D006220:Haloperidol / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced / Q000235:genetics; D008297:Male; D008875:Middle Aged; D011618:Psychotic Disorders / Q000188:drug therapy*
D014150:Antipsychotic Agents; D006220:Haloperidol; D003647:Debrisoquin